Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Nurix Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get NRIX alerts

About Gwenn M. Hansen

The proxy statement of Nurix Therapeutics, Inc. reports total compensation of $2,498,124 for Gwenn M. Hansen in fiscal 2025, including a base salary of $556,000. Disclosed compensation is on record for 7 fiscal years. Nurix Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nurix Therapeutics, Inc. includes Arthur T. Sands (CEO and Board Member), Hans van Houte (CFO), Stefani Wolff (COO) and 7 others.

Affiliation history

Company network

Leadership on record at Nurix Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Nurix Therapeutics, Inc. (NRIX) $556,000 $2,498,124
2024 Nurix Therapeutics, Inc. (NRIX) $510,533 $2,033,860
2023 Nurix Therapeutics, Inc. (NRIX) $493,200 $1,632,757
2022 Nurix Therapeutics, Inc. (NRIX) $476,250 $3,824,583
2021 Nurix Therapeutics, Inc. (NRIX) $433,750 $2,303,328
2020 Nurix Therapeutics, Inc. (NRIX) $391,250 $1,552,577
2019 Nurix Therapeutics, Inc. (NRIX) $299,167 $695,404

Recent activity

No call appearances or filed executive changes recorded yet.